ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Actelion announces changes to its executive team upon completion of the transaction with Johnson & J
May 16, 2017Actelion Ltd (SIX: ATLN) today announced changes to its executive team that would only take effect upon closing of the transaction with Johnson & Johnson expected towards the end of the second quarter 2017. -
Actelion's fourth-quarter sales, profit rise, buoyed by Opsumit, Uptravi
February 15, 2017Actelion announced Tuesday that fourth-quarter sales reached 626.9 million Swiss francs ($622 million), up from 511.8 million francs ($507.7 million) in the year-ago period, boosted by revenue from the pulmonary arterial hypertension (PAH) treatments Opsu -
Actelion's Opsumit fails in late-stage study of PAH due to Eisenmenger syndrome
January 24, 2017Actelion reported Monday that a late-stage study of Opsumit (macitentan) in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger syndrome failed to meet its primary objective.
Pharma Sources Insight January 2025
